G. Steven Burrill

An introduction to Burrill International

Flash required to view this video. Download the latest version here

  

News

Biotech takes a beating in market meltdown October 01, 2008 | Press Release

Biotech outperforms market in May June 02, 2008 | Press Release

Biotech Treads Water in April May 01, 2008 | Press Release

  See all News
Sign up to receive email notifications about our upcoming events and news.


International

Ann F. Hanham

Managing Director

Greater China

Prior to joining Burrill & Company, Ann Hanham was a co-founder and Vice President of Clinical & Regulatory Affairs at InterMune Pharmaceuticals, and prior to that, the Senior Director for Oncology Product Development at Otsuka Pharmaceuticals and the Medical Director for Celtrix Pharmaceuticals. She has also worked for Becton Dickinson in both regulatory and clinical affairs for the monoclonal antibody program, and as a regulatory toxicologist with the Health Protection Branch of Health and Welfare Canada.

Dr. Hanham holds a Ph.D. from the University of British Columbia, an MSc from Simon Fraser University, and a BSc from the University of Toronto. She was also Board Certified in Toxicology in 1986. She currently is a member of the Board of Directors of Adlyfe, BioTie, Cardiokine (observer), Elbion, Endocyte, Logical Therapeutics, SCYNEXIS, and Waterstone.